196 related articles for article (PubMed ID: 18070831)
1. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection.
De Jongh R; Hens R; Basma V; Mouton JW; Tulkens PM; Carryn S
J Antimicrob Chemother; 2008 Feb; 61(2):382-8. PubMed ID: 18070831
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
[TBL] [Abstract][Full Text] [Related]
3. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.
Adembri C; Fallani S; Cassetta MI; Arrigucci S; Ottaviano A; Pecile P; Mazzei T; De Gaudio R; Novelli A
Int J Antimicrob Agents; 2008 Feb; 31(2):122-9. PubMed ID: 18055183
[TBL] [Abstract][Full Text] [Related]
4. A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit.
Mouton JW; Punt N; Vinks AA
Clin Ther; 2005 Jun; 27(6):762-72. PubMed ID: 16117983
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacodynamic interest of ceftazidime continuous infusion vs intermittent bolus administration in patients with severe nosocomial pneumonia].
Cousson J; Floch T; Vernet-Garnier V; Appriou M; Petit JS; Jovenin N; Lamiable D; Hoizey G
Pathol Biol (Paris); 2005; 53(8-9):546-50. PubMed ID: 16023303
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole.
Sprandel KA; Drusano GL; Hecht DW; Rotschafer JC; Danziger LH; Rodvold KA
Diagn Microbiol Infect Dis; 2006 Aug; 55(4):303-9. PubMed ID: 16887471
[TBL] [Abstract][Full Text] [Related]
7. Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC β-lactamase-producing Enterobacteriaceae.
Balakrishnan I; Awad-El-Kariem FM; Aali A; Kumari P; Mulla R; Tan B; Brudney D; Ladenheim D; Ghazy A; Khan I; Virgincar N; Iyer S; Carryn S; Van de Velde S
J Antimicrob Chemother; 2011 Nov; 66(11):2628-31. PubMed ID: 21810837
[TBL] [Abstract][Full Text] [Related]
8. Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration.
Laterre PF; Wittebole X; Van de Velde S; Muller AE; Mouton JW; Carryn S; Tulkens PM; Dugernier T
J Antimicrob Chemother; 2015 Mar; 70(3):891-8. PubMed ID: 25433006
[TBL] [Abstract][Full Text] [Related]
9. Temocillin revived.
Livermore DM; Tulkens PM
J Antimicrob Chemother; 2009 Feb; 63(2):243-5. PubMed ID: 19095679
[TBL] [Abstract][Full Text] [Related]
10. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics.
Ulldemolins M; Roberts JA; Wallis SC; Rello J; Lipman J
J Antimicrob Chemother; 2010 Aug; 65(8):1771-8. PubMed ID: 20530507
[TBL] [Abstract][Full Text] [Related]
11. Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study.
Frippiat F; Musuamba FT; Seidel L; Albert A; Denooz R; Charlier C; Van Bambeke F; Wallemacq P; Descy J; Lambermont B; Layios N; Damas P; Moutschen M
J Antimicrob Chemother; 2015 Jan; 70(1):207-16. PubMed ID: 25216821
[TBL] [Abstract][Full Text] [Related]
12. Continuous infusion versus intermittent administration of cefepime in patients with Gram-negative bacilli bacteraemia.
Jaruratanasirikul S; Sriwiriyajan S; Ingviya N
J Pharm Pharmacol; 2002 Dec; 54(12):1693-6. PubMed ID: 12542901
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of free ertapenem in critically ill septic patients: intermittent versus continuous infusion.
Breilh D; Fleureau C; Gordien JB; Joanes-Boyau O; Texier-Maugein J; Rapaport S; Boselli E; Janvier G; Saux MC
Minerva Anestesiol; 2011 Nov; 77(11):1058-62. PubMed ID: 21597443
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and Pharmacodynamics of Temocillin.
Alexandre K; Fantin B
Clin Pharmacokinet; 2018 Mar; 57(3):287-296. PubMed ID: 28849402
[TBL] [Abstract][Full Text] [Related]
15. Modelled Target Attainment after Temocillin Treatment in Severe Pneumonia: Systemic and Epithelial Lining Fluid Pharmacokinetics of Continuous versus Intermittent Infusions.
Layios N; Visée C; Mistretta V; Denooz R; Maes N; Descy J; Frippiat F; Marchand S; Grégoire N
Antimicrob Agents Chemother; 2022 Mar; 66(3):e0205221. PubMed ID: 35099273
[TBL] [Abstract][Full Text] [Related]
16. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli.
Lorente L; Lorenzo L; Martín MM; Jiménez A; Mora ML
Ann Pharmacother; 2006 Feb; 40(2):219-23. PubMed ID: 16449546
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the pharmacokinetics of piperacillin and sulbactam during intermittent and continuous intravenous infusion.
Langgartner J; Lehn N; Glück T; Herzig H; Kees F
Chemotherapy; 2007; 53(5):370-7. PubMed ID: 17785973
[TBL] [Abstract][Full Text] [Related]
18. Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia.
Boselli E; Breilh D; Rimmelé T; Guillaume C; Xuereb F; Saux MC; Bouvet L; Chassard D; Allaouchiche B
Crit Care Med; 2008 May; 36(5):1500-6. PubMed ID: 18434883
[TBL] [Abstract][Full Text] [Related]
19. Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model.
Alou L; Aguilar L; Sevillano D; Giménez MJ; Echeverría O; Gómez-Lus ML; Prieto J
J Antimicrob Chemother; 2005 Feb; 55(2):209-13. PubMed ID: 15650000
[TBL] [Abstract][Full Text] [Related]
20. Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia.
Boselli E; Breilh D; Duflo F; Saux MC; Debon R; Chassard D; Allaouchiche B
Crit Care Med; 2003 Aug; 31(8):2102-6. PubMed ID: 12973166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
